Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial
Alfons J.M. Van den Eertwegh, Jurjen Versluis, H. Pieter Van den Berg, Saskia J.A.M. Santegoets, R. Jeroen A. Van Moorselaar, Tim M. Van der Sluis, Helen E. Gall, Thomas C. Harding, Karin Jooss, Israel Lowy, Herbert M. Pinedo, Rik J. Scheper, Anita G.M. Stam, B. Mary E. Von Blomberg, Tanja D. De Gruijl, Kristen Hege, Natalie Sacks, Winald R. Gerritsen*
*Corresponding author for this work
Research output: Contribution to journal › Article › Academic › peer-review
311Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial'. Together they form a unique fingerprint.